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Abstract
Background and Aims: The causes of microscopic colitis are currently poorly understood. Previous 
reports have found clinical associations with coeliac disease and genetic associations at the human 
leukocyte antigen [HLA] locus on the ancestral 8.1 haplotype. We investigated pharmacological 
and genetic factors associated with microscopic colitis in the UK Biobank.
Methods: In total, 483 European UK Biobank participants were identified by ICD10 coding, and a genome-
wide association study was performed using BOLT-LMM, with a sensitivity analysis performed excluding 
potential confounders. The HLA*IMP:02 algorithm was used to estimate allele frequency at 11 classical 
HLA genes, and downstream analysis was performed using FUMA. Genetic overlap with inflammatory 
bowel disease [Crohn’s disease and ulcerative colitis] was investigated using genetic risk scores.
Results: We found significant phenotypic associations with smoking status, coeliac disease and 
the use of proton-pump inhibitors but not with other commonly reported pharmacological risk 
factors. Using the largest sample size to date, we confirmed a recently reported association with 
the MHC Ancestral 8.1 Haplotype. Downstream analysis suggests association with digestive tract 
morphogenesis. By calculating genetic risk scores, we also report suggestive evidence of shared 
genetic risk with Crohn’s disease, but not with ulcerative colitis.
Conclusions: This report confirms the role of genetic determinants in the HLA in the pathogenesis 
of microscopic colitis. The genetic overlap with Crohn’s disease suggests a common underlying 
mechanism of disease.
Key Words: Microscopic colitis; genetics; inflammatory bowel disease; ulcerative colitis; Crohn’s disease;  
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1. Introduction
Microscopic colitis includes two related inflammatory bowel dis-
orders, lymphocytic colitis and collagenous colitis that have a 
combined prevalence of 103 cases per 100  000 population.1 Both 
disorders cause chronic watery non-bloody diarrhoea and incontin-
ence, and are associated with normal endoscopic appearances and 
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characteristic histological features. The primary histological feature 
of lymphocytic colitis is patchy lymphocytic infiltration of the epi-
thelium with preserved crypt architecture. Collagenous colitis is char-
acterized by the presence of a thickened subepithelial collagen layer.
The pathogenesis of microscopic colitis is poorly elucidated: it 
reportedly involves immune responses to luminal factors in gen-
etically predisposed individuals.2 A recent association study based 
on Immunochip data reported association between human leuko-
cyte antigen [HLA] alleles on the 8.1 haplotype and collagenous 
colitis3 but not with lymphocytic colitis4 in cohorts that com-
prised 314 patients with collagenous colitis, 122 patients with 
lymphocytic colitis and 4299 controls. Furthermore, Westerlind 
et  al. report genetic overlap with inflammatory bowel disease 
[IBD] by comparing the number of nominally significant single 
nucleotide polymorphisms [SNPs] in both phenotypes.3 The most 
frequently cited environmental risk factors are medications, 
with non-steroidal anti-inflammatory drugs [NSAIDs], proton-
pump inhibitors [PPIs] and selective serotonin reuptake inhibi-
tors [SSRIs] most commonly implicated.5–7 There have been no 
reported investigations of potential pharmacogenetic risk factors 
for microscopic colitis.
We sought to identify phenotypic and genetic associations 
with microscopic colitis in individuals of European ancestry en-
rolled in the UK Biobank, and report subsequent downstream 
analysis. Subsequently, we stratified the data by drug use and 
performed a genome-wide association study [GWAS] to identify 
pharmacogenetic associations. Finally, we calculated genetic risk 
scores for IBD to quantify in detail genetic overlap with micro-
scopic colitis.
2. Methods
2.1. Participants
The UK Biobank is a population-based prospective study com-
prising more than 500  000 UK participants aged 40–69  years 
at time of recruitment between 2006 and 2010. Participants 
are actively followed, and phenotypic data collected include 
demographics, medical conditions, medications, lifestyle and an-
thropometric measurements. SNP genotypes were generated from 
the Affymetrix Axiom UK Biobank array [∼450  000 individuals] 
and the UK BiLEVE array [∼50 000 individuals]. More detail on the 
UK Biobank can be found elsewhere.8
We defined microscopic colitis by the ICD10 code K52.8. The 
full UK Biobank dataset contains 522 K52.8 cases and 502  097 
controls [104.0/100 000 persons]. We stratified the data to contain 
only white Europeans by performing principal component analysis 
in the 1000 Genomes reference panel. Of the 451 099 participants 
remaining, 483 are cases and 450 616 are controls [107.2/100 000 
persons]. Of the 483 cases, 335 [69.4%] had K52.8 as their primary 
diagnosis code.
We investigated pharmacological associations with NSAIDs, 
PPIs and SSRIs using the medication codes reported in the UK 
Biobank [Data-Field 20003: Treatment/medication code]. Drugs 
included and their relative frequencies in the UK Biobank among 
cases and controls are detailed in Supplementary Table 1.
2.2. Statistical Methods
We performed tests for association with clinical characteristics using 
the Mann–Whitney U test for continuous data and Fisher’s exact test 
for categorical data. Probability (p) values are reported uncorrected 
for multiple testing, but we used an adjusted p-value threshold of 
0.0045 for statistical significance for the clinical data.
Quality control of the genotype data was performed centrally by 
the UK Biobank.9 For the GWAS, we used ~12.0 million Haplotype 
Reference Consortium [HRC] imputed variants with an imputation 
r2 ≥ 0.9, minor allele frequency [MAF] ≥ 0.025 [2.5%] and with a 
Hardy–Weinberg equilibrium p > 1 × 10–12. Furthermore, individuals 
with IBD or coeliac disease were excluded from all genetic analyses, 
leaving 423 cases and 445 232 controls.
We performed our main association test using BOLT-LMM v2.3,10 
which applies a linear mixed model [LMM] to adjust for the effects 
of population structure and individual relatedness and allowed us to 
include all related individuals in our white European subset, rather 
than reducing the sample size to only include the unrelated individ-
uals [379 768]. Covariates included were age, sex, recruiting centre 
and genotyping chip. A more detailed explanation of the GWAS meth-
odology can be found in our recent publication,11 and a principal 
components plot is available in Supplementary Figure 1. Odds ratios 
from BOLT-LMM were calculated by OR = eβ / (µ ∗ (1 − µ)) where 
µ = case fraction, and standard errors were divided by (µ ∗ (1 − µ)) 
to give confidence intervals. Following the GWAS, FUMA’s SNP2GENE 
analysis was used to convert SNP data into genomic loci, and to per-
form a gene-set enrichment analysis using MAGMA.12
As a sensitivity analysis we also performed a secondary GWAS 
on a more refined phenotype using only white British unrelated in-
dividuals, in which we excluded coeliac and IBD participants [de-
fined by ICD10, ICD9 and self-report] and participants using PPIs. 
Controls were further refined by excluding those with a diagnosis 
[self-reported or in Hospital Episode Statistics data] before the age 
of 70 years of coronary heart disease, stroke, diabetes, chronic ob-
structive pulmonary disease, renal failure, any cancer [excluding 
non-melanoma skin cancer], and those who had died from any cause 
before the age of 70 years. To further limit the possibility of type 
1 errors, this GWAS was performed using Fisher’s exact test. This 
analysis used 335 cases and 64 300 controls [253 cases and 49 608 
controls following filtering of related individuals].
Imputation of HLA alleles was performed using the 
HLA*IMP:02 algorithm to estimate allele frequency at 11 clas-
sical HLA genes: HLA-A, -B, -C, -DRB5, -DRB4, -DRB3, -DRB1, 
-DQB1, -DQA1, -DPB1 and -DPA1 using reference panels de-
scribed by Motyer et  al.13 This procedure provides accurate 
dosages for 362 SNPs in the HLA region, allowing identifica-
tion of the genetic basis of autoimmune processes with greater 
precision.14
Genetic risk scores for ulcerative colitis [UC], Crohn’s disease 
[CD] and IBD were calculated using odds ratios [ORs] for pre-
viously published SNPs.15 From that study, using only SNPs that 
were genome-wide significant at 5 × 10–8 and also present in our 
imputation panel, we have 145 SNPs for CD, 89 for UC and 162 
for IBD. To quantify genetic overlap, for each IBD phenotype, we 
compared the mean genetic risk score  (GRS) among the micro-
scopic colitis patients with controls [defined as not having UC, CD, 
IBD or microscopic colitis]. A GRS containing N SNPs was calcu-
lated according to the equation below where β is the β-coefficient 
[log OR] representing the association between each SNP and the 
relevant phenotype and di is the estimated dosage. Statistical asso-
ciations are quantified using a two-tailed t-test.
GRS =
N∑
i=1
βi · di
2 H. D. Green et al.
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3. Results
3.1. Clinical Associations
Demographic and drug associations are shown in Table 1. 
Microscopic colitis patients were more likely to be older, female and 
a current smoker. White European UK Biobank participants with 
microscopic colitis had an eight times higher risk of coeliac disease 
and 12 times higher risk of IBD than controls. We found no evidence 
of association with body mass index [BMI] or socioeconomic status 
[defined by the Townsend Deprivation Index].
In terms of drug associations, patients with microscopic colitis 
were twice as likely to be using PPIs [a sub-analysis suggests 1.95 for 
omeprazole, 2.00 for lansoprazole]. We found no significant associ-
ations for SSRIs, NSAIDs or statins when accounting for multiple 
testing. We also performed a sub-analysis of NSAIDs, stratifying by 
COX1 and COX2 inhibitors, but found no significant associations. 
All clinical associations were robust to adjustment for age and sex in 
a multivariable logistic regression model, and testing with or without 
the related individuals.
3.2. GWAS Results
Figure 1 shows a Manhattan plot of all SNPs that passed quality 
control and had p < 0.01. We found a strong association for micro-
scopic colitis on chromosome 6, in the HLA region, with lead SNP 
rs2596560 [OR 0.64, 95% confidence interval 0.56–0.72, p = 3×10–
8, MAF 0.24 vs 0.33]. The odds ratio remained the same at the lead 
SNP [OR 0.64, 95% confidence interval 0.53–0.77, p = 3.3 × 10–6] 
when we performed our secondary analysis, on the refined pheno-
type using Fisher’s exact test.
Summary statistics for all genomic risk loci with p  <  10–5 are 
available in Supplementary Table 2, and the full GWAS summary 
Table 1. Clinical associations with microscopic colitis
Variable Cases Controls p-value
Age at recruitment [years] 61.9 [56.2–65.4] 58.6 [50.5–63.8] 5 × 10–15
Body mass index 26.6 [23.7–29.6] 26.7 [24.1–29.9] 0.195
Townsend Deprivation Index −2.03 [−3.55 to 0.28] −2.27 [−3.70 to 0.23] 0.171
Female 65.6% [317/483] 54.2% [244 531/450 616] 5 × 10–7
Current smoker 14.7% [71/483] 10.4% [46 792/450 616] 0.003
Coeliac disease 3.3% [16/483] 0.4% [1991/450 616] 7 × 10−10
IBD 9.5% [46/483] 0.8% [3896/450 616] 2 × 10−32
Using PPIs 20.3% [98/483] 10.3% [46 397/450 616] 9 × 10−11
Using SSRIs 5.8% [28/483] 4.0% [18 003/450 616] 0.048
Using NSAIDs 28.4% [137/483] 26.3% [118 687/450 616] 0.326
Using statins 19.7% [388/483] 16.3% [73 365/450 616] 0.048
The table shows demographic and drug use associations in the UK Biobank. Continuous variables are reported in terms of median [interquartile range]. All p 
values were computed by a Fisher’s or Mann–Whitney U test. A p value threshold was 0.0045 after Bonferroni correction. Significant associations are in bold type. 
Abbreviations: IBD, inflammatory bowel disease; NSAIDs, non-steroidal anti-inflammatory drugs; SSRIs, selective serotonin reuptake inhibitors; PPIs, proton-
pump inhibitors.
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Figure 1. Manhattan plot showing the –log10[p] values for each single nucleotide polymorphism [SNP] in the HRC Imputation Panel with p < 0.01, computed using 
Bolt-LMM and plotted using an in-house MATLAB script which we have made publicly available on the MATLAB File Exchange.16 The horizontal dashed line is the 
genome-wide significance threshold at p = 5 × 10–8. The strongly significant signal on chromosome 6 lies in the HLA region, with lead SNP rs2596560, p = 3 × 10–8.
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statistics can be found at https://www.ebi.ac.uk/gwas/home. In 
Supplementary Figure 2 we present a QQ plot. The genomics in-
flation factor λ was 1.0000. We also include the top ten results of a 
MAGMA Gene-set Analysis in Supplementary Table 3, in which we 
find a Bonferroni-significant association for digestive tract morpho-
genesis. 17
HLA imputation demonstrated that the SNP rs2596560 associ-
ates with the class I and II alleles that comprise the ancestral major 
histocompatibility [MHC] 8.1 haplotype previously been linked to 
microscopic colitis, with lead SNP B_0801 passing genome-wide 
significance. Results from BOLT-LMM runs on the HLA imputed 
alleles are given in Table 2, with alleles on the MHC 8.1 haplotype 
highlighted in bold.
To follow up on the phenotypic association with PPIs, we sought 
to identify pharmacogenetic associations by using PPIs as an inclu-
sion criterion [comparing PPIs with microscopic colitis and PPIs 
with no microscopic colitis]. However, there were no significant 
genome-wide associations for this GWAS.
3.3. Genetic Overlap with IBD
Table 3 shows the mean CD, UC and IBD genetic risk scores and 95% 
confidence intervals for microscopic colitis patients and controls.
Microscopic colitis patients had a higher genetic risk for all 
three tests, but only CD [p = 0.035] and IBD [p = 0.019] were sig-
nificant at the 5% confidence level, suggesting some shared genetic 
pathway behind microscopic colitis and CD/IBD. These were robust 
to applying the same tests on only the unrelated individuals in the 
UK Biobank as a sensitivity analysis. In Table 4 we show which of 
the known risk loci replicate at p < 0.05 for microscopic colitis, al-
though none of these are significant when Bonferroni correcting the 
p value threshold.
4. Discussion
We have conducted a clinical and genetic case-control study of micro-
scopic colitis in the UK Biobank. We confirm previously reported 
phenotypic associations with age, sex, coeliac disease, smoking status 
and PPIs. In a GWAS, we have confirmed recent reports of associ-
ation with SNPs on the MHC 8.1 haplotype, indicating an immune 
component to the pathogenesis of microscopic colitis. Using genetic 
risk scores, we obtain results consistent with overlap in genetic risk 
factors for CD and IBD but not UC. This may suggest shared genetic 
pathways between these phenotypes.
This is the largest GWAS of microscopic colitis to date, and the 
first to look at genetic overlap between microscopic colitis and IBD 
by using a genetic risk score. The main limitation of the study is that 
the ICD10 coding in the UK Biobank only covers the first decimal 
place: K52.8. We acknowledge two limitations as a consequence: this 
code also includes eosinophilic gastritis and colitis, and we are un-
able to distinguish lymphocytic from collagenous colitis. However, 
eosinophilic gastritis and colitis are of very low prevalence [5.1 and 
2.1/100 000 persons respectively]18 compared to microscopic colitis 
[103.0/100 000 persons].1
The UK Biobank ICD10 data rely on hospital coding data, 
which has limitations in terms of whether patients have had a coded 
diagnosis at hospital, and rely on the accuracy of hospital coding; 
Table 2. Classical HLA alleles 
SNP Allele frequency Beta SE p-value
B_801 0.143 4.3 × 10–4 9.4 × 10–5 3.9 × 10–6
DRB1_301 0.147 3.7 × 10–4 9.2 × 10–5 5.6 × 10–5
DRB3_9901 0.655 −2.6 × 10–4 6.9 × 10–5 1.5 × 10–4
DRB3_101 0.166 3.3 × 10–4 8.8 × 10–5 2.0 × 10–4
DQA1_501 0.230 2.9 × 10–4 7.8 × 10–5 2.1 × 10–4
C_701 0.175 3.2 × 10–4 8.6 × 10–5 2.4 × 10–4
DQB1_201 0.148 3.4 × 10–4 9.2 × 10–5 2.7 × 10–4
The table shows the allele frequencies, beta, standard error and p values of 
all classical HLA alleles with a p value below 5 × 10–4 [computed through Bolt-
LMM] and MAF > 0.01. SNPs in bold are part of the HLA A1-B8-DR3-DQ2 
[ancestral MHC 8.1] haplotype.
Table 3. Genetic risk score means and associations: microscopic 
colitis patients are significantly enriched for genetic risk factors for 
Crohn’s disease and IBD, but not for ulcerative colitis
Disease for which 
genetic risk score 
derived
Mean [95% CI] 
score for  
microscopic  
colitis patients
Mean [95% CI]  
score for controls
p value
Crohn’s disease 0.9688 
[0.9632–0.9739]
0.9634  
[0.9632–0.9636]
0.035
Ulcerative colitis 0.9928 
[0.9859–0.9997]
0.9890 
[0.9888–0.9892]
0.261
IBD 0.9286 
[0.9237–0.9335]
0.9230 
[0.9229–0.9231]
0.019
Abbreviation: IBD, inflammatory bowel disease.
Table 4. Nominally significant SNPs in Crohn’s disease and IBD GRS 
GRS Chromosome Position A1 A1 frequency Beta SE p
Both 10 6081230 C 0.836092 2.2 × 10–4 8.85 × 10–5 1.4 × 10–2
Both 2 28614794 C 0.519615 1.5 × 10–4 6.58 × 10–5 1.9 × 10–2
Both 22 30493882 G 0.55509 1.8 × 10–4 6.58 × 10–5 7.7 × 10–3
Both 17 32593665 A 0.72546 1.6 × 10–4 7.32 × 10–5 3.0 × 10–2
Both 21 45615741 G 0.394392 1.3 × 10–4 6.69 × 10–5 4.7 × 10–2
Both 7 50175654 G 0.573233 −1.7 × 10–4 6.62 × 10–5 1.2 × 10–2
Both 7 50304461 C 0.33364 −1.4 × 10–4 6.94 × 10–5 4.1 × 10–2
Crohn’s disease 12 6491125 G 0.646309 −1.6 × 10–4 6.93 × 10–5 1.8 × 10–2
IBD 7 2869985 T 0.697662 2.3 × 10–4 7.12 × 10–5 1.1 × 10–3
IBD 13 27531267 T 0.82362 2.2 × 10–4 8.58 × 10–5 1.1 × 10–2
Summary statistics of the known risk variants for Crohn’s disease and IBD in our microscopic colitis genome-wide association study for those that pass the 
nominal p value threshold of 0.05. Abbreviation: IBD, inflammatory bowel disease; GRS, genetic risk score.
4 H. D. Green et al.
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however, their use is standard practice in literature performing 
UK Biobank GWASs. This study was performed using only white 
Europeans, and further studies are required to determine if the re-
sults are consistent across other ethnic groups. The UK Biobank also 
only includes patients between the ages of 40 and 69 years at re-
cruitment, although this covers the peak age of onset for microscopic 
colitis. We are confident our main GWAS result is not a false positive 
due to the high MAF of the lead SNP and aligning closely with pre-
vious work, but we acknowledge that due to having under 500 cases, 
there may by many SNPs we were unable to detect due to low OR or 
MAF. A meta-analysis combining the results of this study and others 
may help to identify further associations.
To follow up on the strong association with PPIs, we performed 
a GWAS to find possible underlying pharmacogenetic associations, 
but there were no genome-wide significant SNPs. A follow-up study 
with a dedicated drug-exposed cohort would have greater power 
to detect such associations, as has been demonstrated in our recent 
study of thiopurine-induced myelosuppression.19
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